IMP dehydrogenase mutants: cell culture model for hyperuricemia.

Buddy Ullman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

These studies with wild-type and mutant cells defective in IMP dehydrogenase and the previous data with the adenylosuccinate synthetase-deficient cell line suggest that among the clinical population with dominantly inherited hyperuricemia, patients with partial deficiencies in these enzymes exist. It is hoped that these pharmacogenetic cell culture models for overproduction hyperuricemia will lead to the initiation of a search for hyperuricemia patients with either of these deficiencies. If such patients are found it may be possible to design chemotherapeutic regimens by which effectors (inhibitors) of purine synthesis might ameliorate the overproduction of purines by the de novo pathway.

Original languageEnglish (US)
Pages (from-to)373-379
Number of pages7
JournalAdvances in Experimental Medicine and Biology
Volume165 Pt A
StatePublished - 1984
Externally publishedYes

Fingerprint

Adenylosuccinate Synthase
IMP Dehydrogenase
Hyperuricemia
Purines
Cell culture
Cell Culture Techniques
Cells
Enzymes
Pharmacogenetics
Cell Line
Population
purine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

IMP dehydrogenase mutants : cell culture model for hyperuricemia. / Ullman, Buddy.

In: Advances in Experimental Medicine and Biology, Vol. 165 Pt A, 1984, p. 373-379.

Research output: Contribution to journalArticle

@article{bb129c31621c400e86509b22b74ac41a,
title = "IMP dehydrogenase mutants: cell culture model for hyperuricemia.",
abstract = "These studies with wild-type and mutant cells defective in IMP dehydrogenase and the previous data with the adenylosuccinate synthetase-deficient cell line suggest that among the clinical population with dominantly inherited hyperuricemia, patients with partial deficiencies in these enzymes exist. It is hoped that these pharmacogenetic cell culture models for overproduction hyperuricemia will lead to the initiation of a search for hyperuricemia patients with either of these deficiencies. If such patients are found it may be possible to design chemotherapeutic regimens by which effectors (inhibitors) of purine synthesis might ameliorate the overproduction of purines by the de novo pathway.",
author = "Buddy Ullman",
year = "1984",
language = "English (US)",
volume = "165 Pt A",
pages = "373--379",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - IMP dehydrogenase mutants

T2 - cell culture model for hyperuricemia.

AU - Ullman, Buddy

PY - 1984

Y1 - 1984

N2 - These studies with wild-type and mutant cells defective in IMP dehydrogenase and the previous data with the adenylosuccinate synthetase-deficient cell line suggest that among the clinical population with dominantly inherited hyperuricemia, patients with partial deficiencies in these enzymes exist. It is hoped that these pharmacogenetic cell culture models for overproduction hyperuricemia will lead to the initiation of a search for hyperuricemia patients with either of these deficiencies. If such patients are found it may be possible to design chemotherapeutic regimens by which effectors (inhibitors) of purine synthesis might ameliorate the overproduction of purines by the de novo pathway.

AB - These studies with wild-type and mutant cells defective in IMP dehydrogenase and the previous data with the adenylosuccinate synthetase-deficient cell line suggest that among the clinical population with dominantly inherited hyperuricemia, patients with partial deficiencies in these enzymes exist. It is hoped that these pharmacogenetic cell culture models for overproduction hyperuricemia will lead to the initiation of a search for hyperuricemia patients with either of these deficiencies. If such patients are found it may be possible to design chemotherapeutic regimens by which effectors (inhibitors) of purine synthesis might ameliorate the overproduction of purines by the de novo pathway.

UR - http://www.scopus.com/inward/record.url?scp=0021297691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021297691&partnerID=8YFLogxK

M3 - Article

C2 - 6144250

AN - SCOPUS:0021297691

VL - 165 Pt A

SP - 373

EP - 379

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -